复星医药(600196.SH):HLX13一线治疗不可切除的晚期肝细胞癌患者启动I/III期临床试验

智通财经
May 16, 2025

智通财经APP讯,复星医药(600196.SH)公告,公司控股子公司上海复宏汉霖生物技术股份有限公司及其控股子公司自主研发的伊匹木单抗生物类似药HLX13(重组抗CTLA-4全人单克隆抗体注射液,简称“HLX13”)一线治疗不可切除的晚期肝细胞癌(HCC)患者于中国境内启动I/III期临床试验。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10